Jul 29, 2021
Alkaloid – operating results for January – June 2021
Sales
According to the the unaudited standalone Income Statement, in the period January- June 2021, the sales reached the amount of MKD 4,788,760,106, 1% up compared to the same period last year. Total consolidated sales reached MKD 6,272,411,971, an increase of 3% compared to the same period last year.
Sales by regions and countries
Consolidated sales in the domestic market increased by 7%. The total consolidated export of the company is increased by 1%. Out of the total consolidated sales, 35% were realized in the domestic market, while the foreign markets account for 65%. The breakdown by region shows that the countries of South-East Europe account for 34% of the sales, 20% of the sales were realized in the countries from Western Europe (EU and EFTA), Russia and CIS 10%, while the other markets account for 1% of the total consolidated sales. The highest rise in export markets was seen in Russia and CIS region, increased by 28% and Southeast Europe, increased by 3%.
Sales by group of products
The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals with 88% of total consolidated sales, with OTC products accounting for 20%, antibiotics 18%, cardiovascular products 15%, neurological products 14% etc. The Chemistry Cosmetics Botanicals segment accounts for 12% of the total consolidated sales, or more precisely Chemistry 3%, Cosmetics 7% and Botanicals 2%.
Investments
The total investments in non-current assets for the period January – June 2021 amounted to MKD 524,113,924.
Operating results
Standalone earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 1,065,699,771 marked an increase of roughly 13%, whereas the net profit amounting to MKD 588,962,195 rose by 12%.
Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 1,110,263,703 saw an increase of 13%, whereas the net consolidated profit amounting to MKD 583,524,249 went up by 14%.
Employees
In the period January – June 2021 Alkaloid recruited 121 new employees in the R.N. Macedonia. The management board of Alkaloid AD Skopje reached a decision on approval and payment of holiday allowances for its employees in March 2021 in the amount of 100% of the average net salary paid by a worker in the previous three months in R.N. Macedonia. The amount paid was MKD 31,167 gross or MKD 28,050 net. The Alkaloid Group has 2,479 employees, of which 1,909 in Alkaloid in the country and 570 employees in its subsidiaries and representative offices abroad.
Shares
The shares of Alkaloid AD Skopje have been listed since 2002 and stand as one of the most traded and most liquid shares on the Macedonian Stock Exchange. The share price of Alkaloid AD Skopje in January-June 2021 ranged from MKD 13,300.00 to MKD 16,500.00, with an average of MKD 14,738.30 per share, which is 23.3% up, compared to the average price in the same period in 2020. Alkaloid shares are owned by 5,054 shareholders physical and legal entities and market capitalization on 30.06.2021 was MKD 22.2 billion.
Business plan 2021
The business plan for 2021, adopted by the Managing Board of Alkaloid AD Skopje at its session held on December 29th 2020, anticipates investment of around 12% of the consolidated sales in tangible and intangible assets, a growth in consolidated sales of 7% compared to 2020, as well as a growth in pre-tax consolidated profit of 7% in comparison with 2020.
The business plan for 2021 is based on the expectations, forecasts and opportunities of the current and new markets and products available to the Company at the time of drafting the plan. Circumstances and events in 2021, thus the actual results, may vary from those taken into account in the Business Plan.
Expectations for the upcoming period
In the past period, the company has faced a number of internal and external challenges and emerging risks, generated by the pandemic of COVID 19. We have taken a number of measures so far to neutralize all the negative effects, without compromising the health of employees and the successful operation of the company. In the upcoming period employees’ health remains a top priority as well as maintaining current liquidity, financial stability and realization of the planned goals.